Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma.
作者： Sadahisa Ogasawara , Fumihiko Kanai , Shuntaro Obi , Shinpei Sato , Taketo Yamaguchi
DOI: 10.1007/S12072-010-9249-4
关键词: Internal medicine 、 Sorafenib 、 Hepatology 、 Survival benefit 、 Colorectal surgery 、 Oncology 、 Medicine 、 Hepatocellular carcinoma
摘要: Purpose Sorafenib provides a survival benefit for patients with advanced hepatocellular carcinoma (HCC). However, there has been little experience it in Japan. This study evaluated the safety and tolerance of sorafenib Japanese HCC.
springer.com
sci-hub.se 参考文章(23)
M. Ryu, Y. Shimamura, T. Kinoshita, M. Konishi, N. Kawano, M. Iwasaki, J. Furuse, M. Yoshino, N. Moriyama, M. Sugita, Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Japanese Journal of Clinical Oncology. ,vol. 27, pp. 251- 257 ,(1997) , 10.1093/JJCO/27.4.251
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
Katherine A. McGlynn, Lilian Tsao, Ann W. Hsing, Susan S. Devesa, Joseph F. Fraumeni, International trends and patterns of primary liver cancer International Journal of Cancer. ,vol. 94, pp. 290- 296 ,(2001) , 10.1002/IJC.1456
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jiejun Wang, Won Young Tak, Hongming Pan, Karin Burock, Jessie Zou, Dimitris Voliotis, Zhongzhen Guan, None, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology. ,vol. 10, pp. 25- 34 ,(2009) , 10.1016/S1470-2045(08)70285-7
Junji Furuse, Hiroshi Ishii, Kohei Nakachi, Eiichiro Suzuki, Satoshi Shimizu, Keiko Nakajima, Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma Cancer Science. ,vol. 0, pp. 071113200242005- ??? ,(2007) , 10.1111/J.1349-7006.2007.00648.X
Violaine Ozenne, Valerie Paradis, Simon Pernot, Corinne Castelnau, Marie-Pierre Vullierme, Mohamed Bouattour, Dominique Valla, Olivier Farges, Françoise Degos, Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology & Hepatology. ,vol. 22, pp. 1106- 1110 ,(2010) , 10.1097/MEG.0B013E3283386053
Jordi Bruix, Morris Sherman, Josep M Llovet, Michel Beaugrand, Riccardo Lencioni, Andrew K Burroughs, Erik Christensen, Luigi Pagliaro, Massimo Colombo, Juan Rodés, None, Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference Journal of Hepatology. ,vol. 35, pp. 421- 430 ,(2001) , 10.1016/S0168-8278(01)00130-1
D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 74- 108 ,(2005) , 10.3322/CANJCLIN.55.2.74
Kenichi Takayasu, Shigeki Arii, Iwao Ikai, Masao Omata, Kiwamu Okita, Takafumi Ichida, Yutaka Matsuyama, Yasuni Nakanuma, Masamichi Kojiro, Masatoshi Makuuchi, Yoshio Yamaoka, Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. ,vol. 131, pp. 461- 469 ,(2006) , 10.1053/J.GASTRO.2006.05.021
Takeji Umemura, Tetsuya Ichijo, Kaname Yoshizawa, Eiji Tanaka, Kendo Kiyosawa, Epidemiology of hepatocellular carcinoma in Japan. Hepatology Research. ,vol. 37, ,(2007) , 10.1111/J.1872-034X.2007.00169.X